The Nature of the Cardiac Myxoma
Overview
Authors
Affiliations
Ten archive cases of cardiac myxoma were evaluated for proliferative activity, metastatic potential and expression of oncogene/tumor suppressor gene products by means of PCNA, MIB1, nm23, p53, Bcl-2 and Rb-1 immunohistochemistry. The myxomas showed variable proliferative activity (PCNA 0-41%, average 12.6%, MIB1 0-13%, average 3.2%) contrasting with the absence of mitotic activity histologically. All the myxomas showed nm23 staining. None showed p53 reactivity. Eight cases were negative for Bcl-2 expression, with two cases giving weak cytoplasmic staining. Rb-1 reactivity showed a variable pattern (staining indices 0-86%) paralleling the cases' proliferative activity. The cardiac myxoma is interpreted as a weakly proliferative lesion with little metastatic potential and no modulation of oncogene/oncogene suppressor products. Whilst not excluding a neoplastic aetiology, the results are considered more in keeping with a reactive/hamartomatous process.
Heart myxoma develops oncogenic and metastatic phenotype.
Pacheco-Velazquez S, Gallardo-Perez J, Diaz D, Adan-Ladron de Guevara A, Robledo-Cadena D, Saavedra E J Cancer Res Clin Oncol. 2019; 145(5):1283-1295.
PMID: 30900156 DOI: 10.1007/s00432-019-02897-0.
Oliveira M, Ferreira L, de Campos Zuccari D, Brandi A, Dos Santos C, Botelho P Rev Bras Cir Cardiovasc. 2014; 29(1):83-8.
PMID: 24896167 PMC: 4389473. DOI: 10.5935/1678-9741.20140015.
Molecular basis of cardiac myxomas.
Singhal P, Luk A, Rao V, Butany J Int J Mol Sci. 2014; 15(1):1315-37.
PMID: 24447924 PMC: 3907871. DOI: 10.3390/ijms15011315.
Herpes simplex virus type 1 infection associated with atrial myxoma.
Li Y, Pan Z, Ji Y, Sheppard M, Jeffries D, Archard L Am J Pathol. 2003; 163(6):2407-12.
PMID: 14633612 PMC: 1892371. DOI: 10.1016/S0002-9440(10)63595-X.